JP2018504438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504438A5 JP2018504438A5 JP2017541334A JP2017541334A JP2018504438A5 JP 2018504438 A5 JP2018504438 A5 JP 2018504438A5 JP 2017541334 A JP2017541334 A JP 2017541334A JP 2017541334 A JP2017541334 A JP 2017541334A JP 2018504438 A5 JP2018504438 A5 JP 2018504438A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- hydrogen
- methyl
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 93
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 11
- -1 4-methoxyphenoxy Chemical group 0.000 claims description 10
- 229940125753 fibrate Drugs 0.000 claims description 10
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims description 8
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 7
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 7
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 6
- 229960002297 fenofibrate Drugs 0.000 claims description 6
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims description 4
- 208000005176 Hepatitis C Diseases 0.000 claims description 4
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 4
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims description 4
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 229960000516 bezafibrate Drugs 0.000 claims description 4
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical group C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001214 clofibrate Drugs 0.000 claims description 4
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940125542 dual agonist Drugs 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 4
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- UVYROQLAJUPBJX-KXSSUAHJSA-N (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1.C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 UVYROQLAJUPBJX-KXSSUAHJSA-N 0.000 claims description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 2
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 claims description 2
- 239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 claims description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000014882 Carotid artery disease Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 claims description 2
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 claims description 2
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- HWVNEWGKWRGSRK-UHFFFAOYSA-N GW 0742 Chemical compound CC=1N=C(C=2C=C(F)C(=CC=2)C(F)(F)F)SC=1CSC1=CC=C(OCC(O)=O)C(C)=C1 HWVNEWGKWRGSRK-UHFFFAOYSA-N 0.000 claims description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 206010072877 Intestinal fibrosis Diseases 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 claims description 2
- DAYKLWSKQJBGCS-NRFANRHFSA-N aleglitazar Chemical compound C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 claims description 2
- 208000007474 aortic aneurysm Diseases 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 208000037876 carotid Atherosclerosis Diseases 0.000 claims description 2
- 229960005110 cerivastatin Drugs 0.000 claims description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 2
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims description 2
- 229960002174 ciprofibrate Drugs 0.000 claims description 2
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 claims description 2
- 229950003072 clinofibrate Drugs 0.000 claims description 2
- 229950008441 clofibric acid Drugs 0.000 claims description 2
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 229950003040 dalvastatin Drugs 0.000 claims description 2
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 229960003765 fluvastatin Drugs 0.000 claims description 2
- 229960003627 gemfibrozil Drugs 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 231100000234 hepatic damage Toxicity 0.000 claims description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 230000008818 liver damage Effects 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 229950009116 mevastatin Drugs 0.000 claims description 2
- 229950005171 nicofibrate Drugs 0.000 claims description 2
- RARQHAFNGNPQCZ-UHFFFAOYSA-N nicofibrate Chemical compound C=1C=CN=CC=1COC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RARQHAFNGNPQCZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical group OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 229960002797 pitavastatin Drugs 0.000 claims description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 2
- 208000007232 portal hypertension Diseases 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 229960000672 rosuvastatin Drugs 0.000 claims description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- VPRFDABTJNLKKR-XHZSPPMBSA-N tocofibrate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 VPRFDABTJNLKKR-XHZSPPMBSA-N 0.000 claims description 2
- 229950005856 tocofibrate Drugs 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000003908 liver function Effects 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical group O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- IDNVAAAHBDAMBN-UHFFFAOYSA-N 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole Chemical compound CC1=CSC(C=2C=CC(=CC=2)C(F)(F)F)=N1 IDNVAAAHBDAMBN-UHFFFAOYSA-N 0.000 description 1
- 102100038495 Bile acid receptor Human genes 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- KYAKGJDISSNVPZ-UHFFFAOYSA-N etofylline clofibrate Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYAKGJDISSNVPZ-UHFFFAOYSA-N 0.000 description 1
- 229950009036 etofylline clofibrate Drugs 0.000 description 1
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical group C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- DDDQVDIPBFGVIG-UHFFFAOYSA-N plafibride Chemical compound C1COCCN1CNC(=O)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 DDDQVDIPBFGVIG-UHFFFAOYSA-N 0.000 description 1
- 229950010439 plafibride Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021166629A JP2022000483A (ja) | 2015-02-06 | 2021-10-11 | 併用療法のための医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113134P | 2015-02-06 | 2015-02-06 | |
| US62/113,134 | 2015-02-06 | ||
| PCT/US2016/016694 WO2016127019A2 (en) | 2015-02-06 | 2016-02-05 | Pharmaceutical compositions for combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021166629A Division JP2022000483A (ja) | 2015-02-06 | 2021-10-11 | 併用療法のための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504438A JP2018504438A (ja) | 2018-02-15 |
| JP2018504438A5 true JP2018504438A5 (https=) | 2019-02-14 |
| JP7306791B2 JP7306791B2 (ja) | 2023-07-11 |
Family
ID=56564878
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541334A Active JP7306791B2 (ja) | 2015-02-06 | 2016-02-05 | 併用療法のための医薬組成物 |
| JP2021166629A Withdrawn JP2022000483A (ja) | 2015-02-06 | 2021-10-11 | 併用療法のための医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021166629A Withdrawn JP2022000483A (ja) | 2015-02-06 | 2021-10-11 | 併用療法のための医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US11311557B2 (https=) |
| EP (2) | EP4035665A1 (https=) |
| JP (2) | JP7306791B2 (https=) |
| KR (1) | KR20170115071A (https=) |
| CN (1) | CN107405325B (https=) |
| AR (1) | AR103624A1 (https=) |
| AU (2) | AU2016215179B2 (https=) |
| BR (1) | BR112017016766B1 (https=) |
| CA (1) | CA2976056C (https=) |
| CL (3) | CL2017001983A1 (https=) |
| CO (1) | CO2017007959A2 (https=) |
| CR (1) | CR20170356A (https=) |
| DK (1) | DK3253382T3 (https=) |
| EA (1) | EA036404B1 (https=) |
| EC (1) | ECSP17057848A (https=) |
| ES (1) | ES2905872T3 (https=) |
| GT (1) | GT201700174A (https=) |
| IL (2) | IL253719B (https=) |
| MA (1) | MA40814A1 (https=) |
| MX (1) | MX388508B (https=) |
| NI (1) | NI201700100A (https=) |
| PE (1) | PE20180027A1 (https=) |
| PH (1) | PH12017501384A1 (https=) |
| SG (1) | SG11201706347SA (https=) |
| SV (1) | SV2017005512A (https=) |
| TN (1) | TN2017000344A1 (https=) |
| TW (1) | TW201628625A (https=) |
| UA (1) | UA125744C2 (https=) |
| WO (1) | WO2016127019A2 (https=) |
| ZA (1) | ZA201706007B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA036404B1 (ru) | 2015-02-06 | 2020-11-06 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
| CR20170456A (es) | 2015-04-07 | 2018-06-13 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapias combinadas |
| EP3353189A4 (en) | 2015-09-24 | 2019-06-19 | Intercept Pharmaceuticals, Inc. | METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| US11331292B2 (en) | 2016-03-31 | 2022-05-17 | Genfit | Methods of treatment of cholestatic diseases |
| SMT202500241T1 (it) * | 2016-03-31 | 2025-07-22 | Genfit | Elafibranor per uso nel trattamento di colangite biliare primitiva |
| MX382765B (es) | 2016-12-09 | 2025-03-13 | Zydus Lifesciences Ltd | Tratamiento para la colangitis biliar primaria. |
| JP7618384B2 (ja) * | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| JP2020533339A (ja) * | 2017-09-13 | 2020-11-19 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む組合せ |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| JP7631217B2 (ja) * | 2019-04-10 | 2025-02-18 | ジェンフィット | 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法 |
| SG11202113155XA (en) * | 2019-05-30 | 2021-12-30 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| CN110287493B (zh) * | 2019-06-28 | 2023-04-18 | 中国科学技术信息研究所 | 风险短语识别方法、装置、电子设备及存储介质 |
| EP3999101A1 (en) * | 2019-07-18 | 2022-05-25 | ENYO Pharma | Method for decreasing adverse-effects of interferon |
| CN114727976A (zh) * | 2019-09-20 | 2022-07-08 | 雷内奥制药公司 | PPAR-δ激动剂在肾脏疾病治疗中的用途 |
| CN114929214A (zh) * | 2019-11-22 | 2022-08-19 | 阿沃林特有限公司 | Sglt2抑制剂治疗原发性胆汁性胆管炎的用途 |
| CN111690731B (zh) * | 2020-05-22 | 2021-09-28 | 河南大学 | Fxr激动剂在治疗肝性脑病中的应用 |
| CN115884765A (zh) | 2020-08-26 | 2023-03-31 | 基恩菲特公司 | 用于治疗原发性胆汁性胆管炎的组合物和方法 |
| CN112885471B (zh) * | 2021-03-12 | 2023-01-24 | 上海中医药大学附属岳阳中西医结合医院 | 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统 |
| US20250161326A1 (en) * | 2022-01-28 | 2025-05-22 | Intercept Pharmaceuticals, Inc. | Combination therapy |
| EP4583874A1 (en) * | 2022-12-21 | 2025-07-16 | Charles University, Faculty Of Pharmacy In Hradec Kralove | Multitarget nuclear receptor ligands based on 2-(4-(quinolin-2-yloxy)phenoxy)propanoic acid and 2-(4-(quinoxalin-2-yloxy)phenoxy)propanoic acid for the treatment of metabolic and liver diseases |
| WO2025250918A1 (en) * | 2024-05-30 | 2025-12-04 | Intercept Pharmaceuticals, Inc. | Novel compositions |
| EP4725479A1 (en) * | 2024-10-09 | 2026-04-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Ppar agonists for treatment of diseases associated with aatd |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB860303A (en) | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
| US3262580A (en) | 1964-06-23 | 1966-07-26 | Mcdowell Wellman Eng Co | Slewable gantry crane |
| FR1498459A (https=) | 1965-07-30 | 1968-01-08 | ||
| US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
| US4058552A (en) | 1969-01-31 | 1977-11-15 | Orchimed Sa | Esters of p-carbonylphenoxy-isobutyric acids |
| FI52570C (fi) | 1969-04-16 | 1977-10-10 | Sumitomo Chemical Co | Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi. |
| AT296986B (de) | 1969-08-13 | 1972-03-10 | Merz & Co | Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen |
| DE2230383C3 (de) | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
| JPS5118954B2 (https=) | 1972-02-04 | 1976-06-14 | ||
| US3948973A (en) | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
| DE2308826C3 (de) | 1973-02-22 | 1980-03-27 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel |
| FR2244511B1 (https=) | 1973-07-05 | 1977-07-15 | Roussel Uclaf | |
| ES8101585A1 (es) | 1980-02-15 | 1980-12-16 | Especialidades Farmaco Terape | Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| EP0607536B1 (en) | 1992-12-08 | 2001-01-24 | Ss Pharmaceutical Co., Ltd. | Arylamide derivatives |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| CN1248916A (zh) * | 1997-01-24 | 2000-03-29 | 加利福尼亚大学董事会 | FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途 |
| AP1207A (en) * | 1997-08-29 | 2003-09-20 | Pfizer Prod Inc | Combination therapy. |
| MXPA00004036A (es) | 1997-10-27 | 2006-05-24 | Reddys Lab Ltd Dr | Compuestos triciclicos novedosos y su uso en medicina; proceso para su preparacion y composiciones farmaceuticas que los contienen.. |
| US20030109467A1 (en) | 2001-11-15 | 2003-06-12 | Isis Pharmaceuticals Inc. | Antisense modulation of human FXR expression |
| JP2002532539A (ja) | 1998-12-18 | 2002-10-02 | アボット・ラボラトリーズ | 脂質調節剤を含む新規な製剤 |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| WO2000040965A1 (en) | 1999-01-07 | 2000-07-13 | Tularik, Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
| US6071955A (en) * | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| EP1284723A4 (en) | 2000-04-19 | 2004-06-30 | Borody Thomas J | COMPILATIONS AND THERAPIES FOR HYPERLIPIDEMIA-ASSOCIATED DISEASES |
| WO2002020463A2 (en) | 2000-09-05 | 2002-03-14 | Tularik Inc. | Fxr modulators |
| WO2002024632A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| AU2002308295B2 (en) | 2001-03-12 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| US7259186B2 (en) | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| GB0405349D0 (en) * | 2004-03-10 | 2004-04-21 | Univ Birmingham | Cancer therapy and medicaments therefor |
| EP1734970B1 (en) | 2004-03-12 | 2014-12-31 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using fxr ligands |
| PE20060315A1 (es) * | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| US20060252670A1 (en) | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| US20090131395A1 (en) | 2005-05-05 | 2009-05-21 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| JP2010517931A (ja) | 2006-02-14 | 2010-05-27 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体 |
| US20070197606A1 (en) | 2006-02-22 | 2007-08-23 | Burczynski Frank J | Use of ppar agonists as anti-oxidants |
| CN101534641A (zh) * | 2006-03-22 | 2009-09-16 | 哈佛大学校长及研究员协会 | 治疗高胆固醇血症和动脉粥样硬化的方法和组合物 |
| US8106077B2 (en) | 2006-05-24 | 2012-01-31 | Eli Lilly And Company | Compounds and methods for modulating FXR |
| BRPI0712262A2 (pt) | 2006-05-24 | 2012-07-10 | Lilly Co Eli | agonistas de fxr |
| PT2040713E (pt) * | 2006-06-27 | 2014-10-13 | Intercept Pharmaceuticals Inc | Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr |
| WO2008015763A1 (fr) | 2006-08-04 | 2008-02-07 | Aska Pharmaceutical Co., Ltd. | Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire |
| EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| WO2008039829A2 (en) | 2006-09-26 | 2008-04-03 | Ironwood Pharmaceuticals, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
| CL2007003035A1 (es) * | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| US20080300235A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
| US20080299118A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for the Treatment of Malignancies |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
| US20090163474A1 (en) | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| US20090215748A1 (en) | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| LT2641596T (lt) * | 2009-11-26 | 2018-08-10 | Genfit | 1,3-difenilprop-2-en-1-ono darinių panaudojimas kepenų sutrikimų gydymui |
| NZ734451A (en) | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| AU2013334122B2 (en) | 2012-10-26 | 2017-11-02 | Intercept Pharmaceuticals, Inc. | Process for preparing bile acid derivatives |
| CA2912139C (en) | 2013-05-14 | 2021-04-20 | Roberto Pellicciari | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| US10077268B2 (en) * | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| EA036404B1 (ru) | 2015-02-06 | 2020-11-06 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
| SG11202113155XA (en) | 2019-05-30 | 2021-12-30 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
-
2016
- 2016-02-05 EA EA201791770A patent/EA036404B1/ru unknown
- 2016-02-05 AU AU2016215179A patent/AU2016215179B2/en active Active
- 2016-02-05 MA MA40814A patent/MA40814A1/fr unknown
- 2016-02-05 CA CA2976056A patent/CA2976056C/en active Active
- 2016-02-05 KR KR1020177024607A patent/KR20170115071A/ko not_active Ceased
- 2016-02-05 EP EP21208443.8A patent/EP4035665A1/en active Pending
- 2016-02-05 ES ES16747312T patent/ES2905872T3/es active Active
- 2016-02-05 JP JP2017541334A patent/JP7306791B2/ja active Active
- 2016-02-05 US US15/548,537 patent/US11311557B2/en active Active
- 2016-02-05 UA UAA201708864A patent/UA125744C2/uk unknown
- 2016-02-05 CR CR20170356A patent/CR20170356A/es unknown
- 2016-02-05 DK DK16747312.3T patent/DK3253382T3/da active
- 2016-02-05 TW TW105104019A patent/TW201628625A/zh unknown
- 2016-02-05 PE PE2017001322A patent/PE20180027A1/es unknown
- 2016-02-05 WO PCT/US2016/016694 patent/WO2016127019A2/en not_active Ceased
- 2016-02-05 BR BR112017016766-2A patent/BR112017016766B1/pt active IP Right Grant
- 2016-02-05 MX MX2017010131A patent/MX388508B/es unknown
- 2016-02-05 AR ARP160100332A patent/AR103624A1/es unknown
- 2016-02-05 CN CN201680015586.6A patent/CN107405325B/zh active Active
- 2016-02-05 TN TNP/2017/000344A patent/TN2017000344A1/en unknown
- 2016-02-05 EP EP16747312.3A patent/EP3253382B1/en not_active Revoked
- 2016-02-05 SG SG11201706347SA patent/SG11201706347SA/en unknown
-
2017
- 2017-07-30 IL IL253719A patent/IL253719B/en unknown
- 2017-08-01 PH PH12017501384A patent/PH12017501384A1/en unknown
- 2017-08-03 CL CL2017001983A patent/CL2017001983A1/es unknown
- 2017-08-04 CO CONC2017/0007959A patent/CO2017007959A2/es unknown
- 2017-08-04 NI NI201700100A patent/NI201700100A/es unknown
- 2017-08-04 GT GT201700174A patent/GT201700174A/es unknown
- 2017-08-07 SV SV2017005512A patent/SV2017005512A/es unknown
- 2017-08-31 EC ECIEPI201757848A patent/ECSP17057848A/es unknown
- 2017-09-04 ZA ZA2017/06007A patent/ZA201706007B/en unknown
-
2018
- 2018-04-19 CL CL2018001006A patent/CL2018001006A1/es unknown
- 2018-12-14 CL CL2018003604A patent/CL2018003604A1/es unknown
-
2021
- 2021-02-17 AU AU2021201015A patent/AU2021201015A1/en not_active Abandoned
- 2021-10-11 JP JP2021166629A patent/JP2022000483A/ja not_active Withdrawn
-
2022
- 2022-02-23 IL IL290823A patent/IL290823A/en unknown
- 2022-03-21 US US17/700,317 patent/US12337003B2/en active Active
- 2022-03-21 US US17/700,392 patent/US20220280534A1/en not_active Abandoned
-
2025
- 2025-06-10 US US19/233,923 patent/US20250367217A1/en active Pending
- 2025-06-10 US US19/233,916 patent/US20250367216A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504438A5 (https=) | ||
| AR103624A1 (es) | Composiciones farmacéuticas para terapia de combinación | |
| JP2022116083A5 (https=) | ||
| HRP20241674T1 (hr) | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe | |
| JP2004513076A5 (https=) | ||
| JP2016538254A5 (https=) | ||
| RU2379295C2 (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| Sikorski | Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease | |
| CA2645291A1 (en) | Dibenzyl amine derivatives as cetp inhibitors | |
| JP2003523336A5 (https=) | ||
| JP2002501887A5 (ja) | アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用 | |
| RU2008135153A (ru) | Применение нитрооксипроизводного лекарственного средства для лечения мышечной дистрофии | |
| JP2010047616A5 (https=) | ||
| JP2004516285A5 (https=) | ||
| CA2651598A1 (en) | Compounds for the treatment of metabolic disorders | |
| EP2578574A4 (en) | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF | |
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение | |
| JP2007533760A5 (https=) | ||
| JP2011521992A (ja) | アトルバスタチン４−（ニトロキシ）ブチルエステルおよび脂質低下剤を含む組成物 | |
| JP2007527433A5 (https=) | ||
| RU2005109163A (ru) | НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPARα И PPARγ | |
| JP2010519290A (ja) | 心血管系障害の治療のための併用療法、組成物及び方法 | |
| JP2019516709A5 (https=) | ||
| JP2007530528A5 (https=) | ||
| Liu et al. | Discovery of a peroxisome proliferator activated receptor γ (PPARγ) modulator with balanced PPARα activity for the treatment of type 2 diabetes and dyslipidemia |